Literature DB >> 11243698

HIV-1 Tat protects CD4+ Jurkat T lymphoblastoid cells from apoptosis mediated by TNF-related apoptosis-inducing ligand.

D Gibellini1, M C Re, C Ponti, C Maldini, C Celeghini, A Cappellini, M La Placa, G Zauli.   

Abstract

We have here investigated the effect of TNF-related apoptosis-inducing ligand (TRAIL), a new member of the TNF cytokine superfamily, on the survival of Jurkat lymphoblastoid cell lines stably transfected with plasmids expressing the wild-type or mutated (Cys22) human immunodeficiency virus type 1 (HIV-1) tat gene. Jurkat cells transfected with wild-type tat were resistant to TRAIL-mediated apoptosis, while Jurkat cells mock-transfected with the control plasmid or with a mutated nonfunctional tat cDNA were highly susceptible to TRAIL-mediated apoptosis. Also, pretreatment with low concentrations (10-100 ng/ml) of extracellular synthetic Tat protein partially protected Jurkat cells from TRAIL-mediated apoptosis. Taken together, these results demonstrated that endogenously expressed tat and, to a lesser extent, extracellular Tat block TRAIL-mediated apoptosis. Since it has been shown that primary lymphoid T cells purified from HIV-1-infected individuals are more susceptible than those purified from normal individuals to TRAIL-mediated apoptosis, our findings underscore a potentially important role of Tat in protecting HIV-1-infected cells from TRAIL-mediated apoptosis. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11243698     DOI: 10.1006/cimm.2000.1746

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  12 in total

1.  TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.

Authors:  Sekar Natesampillai; Ana C Paim; Nathan W Cummins; Aswath P Chandrasekar; Gary D Bren; Sharon R Lewin; Hans-Peter Kiem; Andrew D Badley
Journal:  J Immunol       Date:  2019-06-12       Impact factor: 5.422

Review 2.  The signaling and apoptotic effects of TNF-related apoptosis-inducing ligand in HIV-1 associated dementia.

Authors:  Y Huang; N Erdmann; J Zhao; J Zheng
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

Review 3.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

4.  A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.

Authors:  S M Agwale; M T Shata; M S Reitz; V S Kalyanaraman; R C Gallo; M Popovic; D M Hone
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-02       Impact factor: 11.205

5.  Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.

Authors:  Yida Yang; Ilia Tikhonov; Tracy J Ruckwardt; Mahmoud Djavani; Juan Carlos Zapata; C David Pauza; Maria S Salvato
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

6.  Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis.

Authors:  T O Garnett; M Filippova; P J Duerksen-Hughes
Journal:  Cell Death Differ       Date:  2006-03-10       Impact factor: 15.828

Review 7.  Mechanisms of HIV-associated lymphocyte apoptosis: 2010.

Authors:  N W Cummins; A D Badley
Journal:  Cell Death Dis       Date:  2010-11-11       Impact factor: 8.469

Review 8.  Anti-apoptotic mechanisms of HIV: lessons and novel approaches to curing HIV.

Authors:  Nathan W Cummins; Andrew D Badley
Journal:  Cell Mol Life Sci       Date:  2012-12-30       Impact factor: 9.261

Review 9.  Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.

Authors:  Theodoros Kelesidis; Judith S Currier; Otto O Yang; Todd T Brown
Journal:  AIDS Rev       Date:  2014 Jul-Sep       Impact factor: 2.381

10.  Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment.

Authors:  Milton W Taylor; Takuma Tsukahara; Jeanette N McClintick; Howard J Edenberg; Paul Kwo
Journal:  J Transl Med       Date:  2008-11-05       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.